This case study explores how a health system customer utilized Sentri7® Pharmacy to target high-cost antibiotics, to decrease spend and uphold high-quality patient care.
Looking across a large health system enterprise, a system director of pharmacy saw an opportunity to educate prescribers about a high-cost antibiotic to improve appropriate prescribing in accordance to the system’s AMS program. The antibiotic, ertapenem (INVANZ), has been considered a niche carbapenem due to its lack of antipseudomonal activity. While its once daily dosing is beneficial in outpatient or home infusion settings, it was identified as a target for an inpatient drug initiative in five key hospitals.
